Étiquette : troubles neurologiques

Harmful Effects of Smoking Cannabis : A Cerebrovascular and Neurological Perspective, Sabrina Rahman Archie et al., 2019

Harmful Effects of Smoking Cannabis : A Cerebrovascular and Neurological Perspective Sabrina Rahman Archie and Luca Cucullo Frontiers in Pharmacology, 2019, 10, Article 1481. doi : 10.3389/fphar.2019.01481   Apart from being used as a medicine, cannabis or marijuana is the most widely abused recreational drug all over the world. The legalization and decriminalization of cannabis in Canada and various states of USA may be the underlying reason of the widespread popularity of it among young population. Various studies have reported about the relationship between cannabis use and different detrimental effects like cardiovascular, cerebrovascular, and neurological complications among different age groups. Specifically, the young population is [...]

Lire la suite

“Go Ask Alice”: The Case for Researching Schedule I Drugs, Kenneth V. ISERSON , 2019

“Go Ask Alice”: The Case for Researching Schedule I Drugs Kenneth V. ISERSON Cambridge Quarterly of Healthcare Ethics, 2019, 28, 168–177. © Cambridge University Press 2018. doi : 10.1017/S0963180118000518   Abstract : The available treatments for disorders affecting large segments of the population are often costly, complex, and only marginally effective, and many have numerous side effects. These disorders include dementias, debilitating neurological disorders, the multiple types of drug addiction, and the spectrum of mental health disorders. Preliminary studies have shown that a variety of psychedelic and similar U.S. Drug Enforcement Administration Schedule I drugs may offer better treatment options than those that currently exist and pose potentially [...]

Lire la suite

Malades de Parkinson à Marseille, ils vont tester le cannabis thérapeutique, La Provence, 24/1/2020

Malades de Parkinson à Marseille, ils vont tester le cannabis thérapeutique La Provence, 24/1/2020 https://www.laprovence.com/article/societe/5858706/avant-premiere-malades-de-parkinson-a-marseille-ils-vont-tester-le-cannabis-therapeutique.html transmis par principesactifs.fr La prise de cannabis peut-elle soulager certains symptômes moteurs et non-moteurs de la maladie de Parkinson ? "Nous avons de bonnes raisons de le penser mais nous avons besoin de données robustes pour le démontrer", sourit le Pr Olivier Blin, chef du service de pharmacologie clinique de la Timone, à Marseille. Grâce au soutien du centre d’excellence Dhune et de l’association France-Parkinson, son équipe, avec le service de neurologie et de pathologie du mouvement, le CNRS et l’Institut de neurosciences du CHU s’apprêtent à tester la prise de [...]

Lire la suite

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders, Giovanna Felipe Cavalcante e Costa et al., 2018

The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders Giovanna Felipe Cavalcante e Costa, Hisao Nishijo, Leonardo Ferreira Caixeta, and Tales Alexandre Aversi-Ferreira Hindawi - Evidence-Based Complementary and Alternative Medicine, Volume 2018, Article ID 7686913, 27 pages Doi : 10.1155/2018/7686913   Abstract For neurological disorders, pharmacological tests have shown promising results in the reduction of side effects when using plants with known therapeutic effects in the treatment of some types of dementia. Therefore, the goals of this study are to gather data about the major medicinal plants used in the nervous system as described in ethnopharmacological surveys from South [...]

Lire la suite

Adolescent Cannabis Use : What is the Evidence for Functional Brain Alteration ?, V. Lorenzetti et al., 2016

Adolescent Cannabis Use : What is the Evidence for Functional Brain Alteration ? V. Lorenzetti, S. Alonso-Lanaa, G. J. Youssef, A. Verdejo-Garcia, C. Suo, J. Cousijn, M. Takagi, M. Yücel and N. Solowij Current Pharmaceutical Design, 2016, 22, 1-14. DOI: 10.2174/1381612822666160805155922   Abstract Background : Cannabis use typically commences during adolescence, a period during which the brain undergoes profound remodeling in areas that are high in cannabinoid receptors and that mediate cognitive control and emotion regulation. It is therefore important to determine the impact of adolescent cannabis use on brain function. Objective : We investigate the impact of adolescent cannabis use on brain function by reviewing the functional [...]

Lire la suite

Cannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System, Patrícia Schonhofen et al., 2018

Cannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System Patrícia Schonhofen, Ivi Juliana Bristot, José Alexandre Crippa, Jaime Eduardo Cecílio Hallak, Antônio Waldo Zuardi, Richard B. Parsons, Fábio Klamt CNS Drugs, 2018, 32, (Suppl 1), 1-16. Springer Nature Switzerland, Doi : 10.1007/s40263-018-0550-4 Abstract The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components—cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes—are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor [...]

Lire la suite

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings, Sonja ELSAID, 2019

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Molecular Basis of Neuropsychiatric Disorders : from Bench to Bedside Sonja ELSAID, Stefan KLOIBER, Bernard Le FOLL Progress in Molecular Biology and Translational Science, 2019, 167, 25-75. doi : 10.1016/bs.pmbts.2019.06.005. Cannabis sativa (cannabis) is on of the oldest plants cultivated by men. Cannabidiol (CBD) is the major non-psychomimetic compound derived from cannabis. It has been proposed to have a therapeutic potential over a wide range of neuropsychiatric disorders. In this narrative review, we have summarized a selected number of pre-clinical and clinical studies, examining the effects of CBD in neuropsychiatric [...]

Lire la suite

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry, Gioacchino Calapai et al., 2019

Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry Gioacchino Calapai, Carmen Mannucci, Ioanna Chinou, Luigi Cardia, Fabrizio Calapai, Emanuela Elisa Sorbara, Bernardo Firenzuoli, Valdo Ricca, Gian Franco Gensini and Fabio Firenzuoli Hindawi - Evidence-Based Complementary and Alternative Medicine, 2019, Article ID 2509129, 11 pages https://doi.org/10.1155/2019/2509129   Background : Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective. &e aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD [...]

Lire la suite

Endocannabinoid System in Neurological Disorders, Roberta Ranieri et al., 2016

Endocannabinoid System in Neurological Disorders (Endocannabinoid System and Neurodegeneration) Roberta Ranieri, Chiara Laezza, Maurizio Bifulco, Daniela Marasco and Anna Maria Malfitano Recent Patents on CNS Drug Discovery, 2015, Vol. 10, No. 2, 24 p. Abstract : Background : Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others. Methods : In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease and discuss the main findings about the use [...]

Lire la suite

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ?, Chung Mo Koo et al., 2017

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ? Chung Mo Koo, Hoon-Chul Kang Journal of Epilepsy Research, 2017, 7, 16-20. pISSN 2233-6249 / eISSN 2233-6257 www.kes.or.kr   Epilepsy is an important disease that affects brain function, particularly in those under 3 years old. Uncontrolled seizures can affect cognitive function and quality of life. For these reasons, many trials have been conducted to investigate treatments for pediatric epilepsy. Currently, many antiepileptic drugs are available for the treatment of epilepsy, but cases of intractable epilepsy continue to exist. In the past, cannabis has been tested as a potential treatment of intractable epilepsy. Since [...]

Lire la suite